$TCRT
Alaunos Therapeutics, Inc.

2013 Q4 Form 10-Q Financial Statement

#000119312513406591 Filed on October 22, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.200M $3.070M $5.710M
YoY Change 3.45% -46.23% 52.67%
% of Gross Profit
Research & Development $2.720M $6.247M $16.22M
YoY Change -92.22% -61.47% 51.97%
% of Gross Profit
Depreciation & Amortization $160.0K $180.0K $200.0K
YoY Change -15.79% -10.0% 185.71%
% of Gross Profit
Operating Expenses $6.920M $6.247M $16.22M
YoY Change -82.27% -61.47% 12.53%
Operating Profit -$6.719M -$9.115M -$21.73M
YoY Change -82.7% -58.05% 52.91%
Interest Expense -$1.790M -$7.410M $3.950M
YoY Change -120.89% -287.59% -70.5%
% of Operating Profit
Other Income/Expense, Net -$390.0K -$191.0K -$42.00K
YoY Change -880.0% 354.76% -310.0%
Pretax Income -$8.900M -$16.71M -$17.82M
YoY Change -70.56% -6.23% 2127.5%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.903M -$16.71M -$17.82M
YoY Change -70.54% -6.23% 2122.44%
Net Earnings / Revenue -4451.5% -8356.5% -8912.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.09 -$0.20 -$0.23
COMMON SHARES
Basic Shares Outstanding 83.70M shares 83.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $68.20M $23.60M $95.30M
YoY Change -6.96% -75.24% -19.85%
Cash & Equivalents $68.20M $23.63M $95.33M
Short-Term Investments
Other Short-Term Assets $1.900M $3.200M $7.200M
YoY Change -72.46% -55.56% 414.29%
Inventory
Prepaid Expenses
Receivables $100.0K $400.0K $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $70.30M $27.28M $102.6M
YoY Change -12.43% -73.42% -14.78%
LONG-TERM ASSETS
Property, Plant & Equipment $801.0K $1.336M $2.100M
YoY Change -59.83% -36.38% 133.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $528.0K $739.0K $1.000M
YoY Change -47.25% -26.1% 0.0%
Total Long-Term Assets $1.457M $2.203M $3.000M
YoY Change -53.42% -26.57% 57.89%
TOTAL ASSETS
Total Short-Term Assets $70.30M $27.28M $102.6M
Total Long-Term Assets $1.457M $2.203M $3.000M
Total Assets $71.75M $29.48M $105.6M
YoY Change -13.97% -72.09% -13.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $422.0K $891.0K $4.200M
YoY Change -72.03% -78.79% 90.91%
Accrued Expenses $6.357M $11.57M $16.70M
YoY Change -61.51% -30.7% 89.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.791M $13.36M $21.70M
YoY Change -58.7% -38.42% 83.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.00K $20.00K $24.90M
YoY Change -99.92% -5.68%
Total Long-Term Liabilities $20.00K $20.00K $24.90M
YoY Change -99.92% -5.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.791M $13.36M $21.70M
Total Long-Term Liabilities $20.00K $20.00K $24.90M
Total Liabilities $22.37M $25.85M $46.60M
YoY Change -36.01% -44.53% 21.99%
SHAREHOLDERS EQUITY
Retained Earnings -$340.8M
YoY Change 20.14%
Common Stock $386.6M $331.9M
YoY Change 18.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.38M $3.631M $59.00M
YoY Change
Total Liabilities & Shareholders Equity $71.75M $29.48M $105.6M
YoY Change -13.97% -72.09% -13.65%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$8.903M -$16.71M -$17.82M
YoY Change -70.54% -6.23% 2122.44%
Depreciation, Depletion And Amortization $160.0K $180.0K $200.0K
YoY Change -15.79% -10.0% 185.71%
Cash From Operating Activities -$9.050M -$15.50M -$14.70M
YoY Change -57.91% 5.44% 32.43%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $0.00 $370.0K
YoY Change -87.5% -100.0% -11.9%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$10.00K $0.00 -$370.0K
YoY Change -87.5% -100.0% -11.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $57.60M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 53.63M 200.0K 20.00K
YoY Change -12017.78% 900.0% -87.5%
NET CHANGE
Cash From Operating Activities -9.050M -15.50M -14.70M
Cash From Investing Activities -10.00K 0.000 -370.0K
Cash From Financing Activities 53.63M 200.0K 20.00K
Net Change In Cash 44.57M -15.30M -15.05M
YoY Change -302.32% 1.66% 32.48%
FREE CASH FLOW
Cash From Operating Activities -$9.050M -$15.50M -$14.70M
Capital Expenditures $10.00K $0.00 $370.0K
Free Cash Flow -$9.060M -$15.50M -$15.07M
YoY Change -58.02% 2.85% 30.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2006Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
5.09
CY2007Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
5.75
CY2005Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
3.93
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95333000
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83681579 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2996068 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.73
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5730169 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1565070 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5675997 shares
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.95
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10392387 shares
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.95
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83681579 shares
CY2013Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2133000
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13362000
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
891000
CY2013Q3 us-gaap Other Additional Capital
OtherAdditionalCapital
3657000
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
20000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
3631000
CY2013Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
331817000
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11573000
CY2013Q3 us-gaap Liabilities
Liabilities
25847000
CY2013Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
349000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
84000
CY2013Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
98000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29478000
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
739000
CY2013Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1336000
CY2013Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
22680000
CY2013Q3 us-gaap Assets
Assets
29478000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23631000
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2203000
CY2013Q3 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
331927000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4255000
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
8800000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4215000
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3195000
CY2013Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
449000
CY2013Q3 us-gaap Assets Current
AssetsCurrent
27275000
CY2013Q3 ziop Warrants Liability
WarrantsLiability
9983000
CY2013Q3 ziop Warrant Liabilities Fair Value Disclosure
WarrantLiabilitiesFairValueDisclosure
9983000
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83696029 shares
CY2009Q4 ziop Estimated Fair Value Of Warrant
EstimatedFairValueOfWarrant
22900000
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Risk Free Interest Rate
ClassOfWarrantOrRightFairValueAssumptionRiskFreeInterestRate
0.0214 pure
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Expected Life
ClassOfWarrantOrRightFairValueAssumptionExpectedLife
5 Y
CY2009Q4 ziop Class Of Warrant Term
ClassOfWarrantTerm
P5Y
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Stock Volatility
ClassOfWarrantOrRightFairValueAssumptionStockVolatility
1.05 pure
CY2009Q4 ziop Class Of Warrant Or Right Fair Value Assumption Expected Dividend Yield
ClassOfWarrantOrRightFairValueAssumptionExpectedDividendYield
0.00 pure
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104713000
CY2012Q1 ziop Common Stock Price Per Share1
CommonStockPricePerShare1
5.20
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83236840 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3683786 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.11
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7147303 shares
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.56
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11197454 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83236840 shares
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2733000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18864000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1509000
CY2012Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
6909000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
48445000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
325177000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
800000
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16516000
CY2012Q4 us-gaap Liabilities
Liabilities
34959000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
400000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
83000
CY2012Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
39000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83404000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1001000
CY2012Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
133000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1994000
CY2012Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
72002000
CY2012Q4 us-gaap Assets
Assets
83404000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73306000
CY2012Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3972000
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
283724000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6912000
CY2012Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
58000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
80276000
CY2012Q4 ziop Warrants Liability
WarrantsLiability
12962000
CY2012Q4 ziop Warrant Liabilities Fair Value Disclosure
WarrantLiabilitiesFairValueDisclosure
12962000
dei Trading Symbol
TradingSymbol
ZIOP
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.57
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M21D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1551400 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2398366 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.55
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16553734 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83051151 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.94
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50464000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y9M
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
570168 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.68
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M5D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y9M
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-5000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
119000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
2979000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
956000
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-194000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-190000
us-gaap Interest Paid
InterestPaid
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3717000
us-gaap Contracts Revenue
ContractsRevenue
600000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-262000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2979000
us-gaap Operating Income Loss
OperatingIncomeLoss
-50992000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
250000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
391000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4943000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-618000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
20000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
956000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-118000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40133000
ziop Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
201000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
508700 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77605590 shares
us-gaap Net Income Loss
NetIncomeLoss
-48203000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2482000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11459000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
907000
us-gaap Share Based Compensation
ShareBasedCompensation
2482000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
51592000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
250000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
582000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-49675000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
8000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-600000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
201000
ziop Milestone Payment Under License Agreement
MilestonePaymentUnderLicenseAgreement
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.56
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57332000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17481779 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
42000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1482000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-2516000
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-48000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-65000
us-gaap Interest Paid
InterestPaid
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5922000
us-gaap Contracts Revenue
ContractsRevenue
600000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
47000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2516000
us-gaap Operating Income Loss
OperatingIncomeLoss
-63326000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
96000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-66000
us-gaap Net Income Loss
NetIncomeLoss
-65907000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
412000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15462000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49434000
us-gaap Share Based Compensation
ShareBasedCompensation
3482000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
63926000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
466000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9380000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
226000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-600000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
330000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5861000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2521000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1482000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48464000
ziop Reclassification Of Warrant Liabilities To Equity
ReclassificationOfWarrantLiabilitiesToEquity
412000
ziop Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
49170000
CY2006Q2 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2013-05-03
CY2006Q2 ziop Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
706708 shares
CY2007Q1 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2012-02-23
CY2007Q1 ziop Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
1359317 shares
CY2005Q2 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2012-05-31
CY2005Q2 ziop Class Of Warrant Or Right Issued In Period
ClassOfWarrantOrRightIssuedInPeriod
579 shares
CY2009 ziop Warrants To Purchase Aggregate Shares Of Common Stock
WarrantsToPurchaseAggregateSharesOfCommonStock
8206520 shares
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M11D
CY2012 ziop Milestone Payment Under License Agreement
MilestonePaymentUnderLicenseAgreement
250000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-272104000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
129000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4745000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
13750000
us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-251000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4511000
us-gaap Interest Paid
InterestPaid
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3195000
us-gaap Contracts Revenue
ContractsRevenue
2067000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
739000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
13750000
us-gaap Operating Income Loss
OperatingIncomeLoss
-350188000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3117000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
449000
us-gaap Net Income Loss
NetIncomeLoss
-331927000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
352000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
99777000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
300478000
us-gaap Share Based Compensation
ShareBasedCompensation
22663000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
352255000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3156000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
23631000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
447000
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
500000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2933000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
13280000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
11573000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
891000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
20000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2329000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4743000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
252478000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
16760000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
36151000
ziop Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
270726000
ziop Issuance Of Warrants To Placement Agent In Public Offering
IssuanceOfWarrantsToPlacementAgentInPublicOffering
47276000
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52600000
CY2012Q1 ziop Common Stock Shares Sold
CommonStockSharesSold
10114401 shares
CY2013Q2 ziop Number Of Employee Positions Eliminated
NumberOfEmployeePositionsEliminated
65 Position
CY2013Q2 us-gaap Severance Costs1
SeveranceCosts1
1700000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
76300 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8337 pure
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0104 pure
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78670222 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.95
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0079 pure
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8351 pure
CY2012Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
3945000
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-42000
CY2012Q3 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21727000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-17824000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5712000
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1191000
CY2012Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
21927000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16215000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
125000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9496 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0174 pure
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83161927 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.47
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0161 pure
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9564 pure
CY2013Q3 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-7407000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-191000
CY2013Q3 us-gaap Contracts Revenue
ContractsRevenue
200000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9115000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-16713000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3068000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
809000
CY2013Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9315000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6247000

Files In Submission

Name View Source Status
0001193125-13-406591-index-headers.html Edgar Link pending
0001193125-13-406591-index.html Edgar Link pending
0001193125-13-406591.txt Edgar Link pending
0001193125-13-406591-xbrl.zip Edgar Link pending
d600326d10q.htm Edgar Link pending
d600326dex311.htm Edgar Link pending
d600326dex312.htm Edgar Link pending
d600326dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g600326img001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20130930.xml Edgar Link completed
ziop-20130930.xsd Edgar Link pending
ziop-20130930_cal.xml Edgar Link unprocessable
ziop-20130930_def.xml Edgar Link unprocessable
ziop-20130930_lab.xml Edgar Link unprocessable
ziop-20130930_pre.xml Edgar Link unprocessable